Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.

Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX). Such investors are ...

Edgewise Therapeutics (EWTX) Overview. Read detailed company information including current share prices, financial summary, directors, announcements, dividends & news. Find out more at Intelligent ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat.com ...

Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a look at where Edgewise Therapeutics, Inc.

Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a biopharmaceutical company, focuses on developing therapies for the treatment of muscle disorders. The one-month return of Edgewise Therapeutics, Inc.

Edgewise Therapeutics Inc. (EWTX) stock has reached a remarkable 52-week high, touching $30.14 amidst a year of significant growth. The biopharmaceutical company, which focuses on developing therapies ...